ACS Medicinal Chemistry Letters
Letter
(3) Tsibris, A. M. N.; Kuritzkes, D. R. Chemokine antagonists as
therapeutics: Focus on HIV-1. Annu. Rev. Med. 2007, 58, 445−459.
(4) Haskell, C. A.; Horuk, R. Lymphocyte Trafficking in Health and
Disease. In Progress in Inflammation Research; Badolato, R., Sozzani, S.,
(20) Atwood, J. D. Integrated Rate Expressions. In Inorganic and
Organometallic Reaction Mechanisms; Brooks/Cole Publishing: Monte-
rey, CA, 1985; pp 3−17.
(21) Freedman, T. B.; Cao, X.; Nafie, L. A.; Kalbermatter, M.; Linden,
A.; Rippert, A. J. An unexpected atropisomerically stable 1,1-biphenyl at
ambient temperature in solution, elucidated by vibrational circular
dichroism (VCD). Helv. Chim. Acta 2003, 86, 3141−3155.
(22) Stephens, P. J.; Devlin, F. J.; Pan, J.-J. The determination of the
absolute configurations of chiral molecules using vibrational circular
dichroism (VCD) spectroscopy. Chirality 2008, 20, 643−663.
(23) Freedman, T. B.; Cao, X.; Dukor, R. K.; Nafie, L. A. Absolute
configuration determination of chiral molecules in the solution state
using vibrational circular dichroism. Chirality 2003, 15, 743−748.
(24) Jalkanen, K. J.; Suhai, S. N-Acetyl-L-alanine N′-methylamide: a
density functional analysis of the vibrational absorption and vibrational
circular dichroism spectra. Chem. Phys. 1996, 208, 81−116.
(25) Reversible first-order kinetics calculations (ref 21) reveal that,
starting from pure C + D, 93:7 enantiomeric ratio of A + B/C + D will be
reached after 4 days at 37 °C.
(26) Thoma, G.; Nuninger, F.; Schaefer, M.; Akyel, K. G.; Albert, R.;
Beerli, C.; Bruns, C.; Francotte, E.; Luyten, M.; MacKenzie, D.; Oberer,
L.; Streiff, M. B.; Wagner, T.; Walter, H.; Weckbecker, G.; Zerwes, H.-G.
Orally bioavailable competitive CCR5 antagonists. J. Med. Chem. 2004,
47, 1939−1955.
(27) Palani, A.; Shapiro, S.; Clader, J. W.; Greenlee, W. J.; Blythin, D.;
Cox, K.; Wagner, N. E.; Strizki, J.; Baroudy, B. M.; Dand, N. Bioorg. Med.
Chem. Lett. 2003, 13, 705−708.
Eds.; Birkhauser: Basel, Switzerland, 2006; pp 181−196.
̈
(5) Zlotnik, A. Chemokines and cancer. Int. J. Cancer 2006, 119, 2026−
2029.
(6) Wells, T. N. C.; Power, C. A.; Shaw, J. P.; Proudfoot, A. E. I.
Chemokine blockers: Therapeutics in the making? Trends Pharmacol.
Sci. 2006, 27, 41−47.
(7) Dorr, P.; Westby, M.; Dobbs, D.; Griffin, P.; Irvine, B.; Macartney,
M.; Mori, J.; Rickett, G.; Smith-Burchnell, C.; Napier, C.; Webster, R.;
Armour, D.; Price, D.; Stammen, B.; Wood, A.; Perros, M. Maraviroc
(UK-427,857), a potent, orally bioavailable, and selective small-
molecule inhibitor of chemokine receptor CCR5 with broad-spectrum
anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents
Chemother. 2005, 49, 4721−4732.
́
(8) Gomez-Reino, J. J.; Pablos, J. L.; Carreira, P. E.; Santiago, B.;
Serrano, L.; Vicario, J. L.; Balsa, A.; Figueroa, M.; De Juan, M. D.
Association of rheumatoid arthritis with a functional chemokine
receptor, CCR5. Arthritis Rheum. 1999, 42, 989−992.
(9) Fildes, J. E.; Walker, A. H.; Howlet, R.; Bittar, M. N.; Hutchinson, I.
V.; Leonard, C. T.; Yonanemail, N. Donor CCR5 Δ32 polymorphism
and outcome following cardiac transplantation. Transplant. Proc. 2005,
37, 2247.
(10) Ajuebor, M. N.; Aspinall, A. I.; Zhou, F.; Le, T.; Yang, Y.;
Urbanski, S. J.; Sidobre, S.; Kronenberg, M.; Hogaboam, C. M.; Swain,
M. G. Lack of chemokine receptor CCR5 promotes murine fulminant
liver failure by preventing the apoptosis of activated CD1d-restricted
NKT cells. J. Immunol. 2005, 174, 8027−8037.
(11) Ajuebor, M. N.; Carey, J. A.; Swain, M. G. CCR5 in T cell-
mediated liver diseases: What’s going on? J. Immunol. 2006, 177, 2039−
2045.
(28) McCombie, S. W.; Tagat, J. R.; Vice, S. F.; Lin, S.-I.; Steensma, R.;
Palani, A.; Neustadt, B. R.; Baroudy, B. M.; Strizki, J. M.; Endres, M.;
Cox, K.; Dan, N.; Chou, C.-C. Piperazine-based CCR5 antagonists as
HIV-1 inhibitors. III: Synthesis, antiviral and pharmacokinetic profiles of
symmetrical heteroaryl carboxamides. Bioorg. Med. Chem. Lett. 2003,
567−571.
(12) Ajuebor, M. N.; Wondimu, Z.; Hogaboam, C. M.; Le, T.;
Proudfoot, A. E. I.; Swain, M. G. CCR5 deficiency drives enhanced
natural killer cell trafficking to and activation within the liver in Murine
T cell-mediated hepatitis. Am. J. Pathol. 2007, 170, 1975−1988.
(13) Moreno, C.; Gustot, T.; Nicaise, C.; Quertinmont, E.; Nagy, N.;
̀
Parmentier, M.; Le Moine, O.; Deviere, J.; Louis, H. CCR5 deficiency
exacerbates T-cell-mediated hepatitis in mice. Hepatology 2005, 42,
854−862.
(14) Jones, K. L.; Maguire, J. J.; Davenport, A. P. Chemokine receptor
CCR5: from AIDS to atherosclerosis. Br. J. Pharmacol. 2011, 162, 1453−
1469.
(15) Gonzalez, E.; Kulkarni, H.; Bolivar, H.; Mangano, A.; Sanchez, R.;
Catano, G.; Nibbs, R. J.; Freedman, B. I.; Quinones, M. P.; Bamshad, M.
J.; Murthy, K. K.; Rovin, B. H.; Bradley, W.; Clark, R. A.; Anderson, S. A.;
O’Connell, R. J.; Agan, B. K.; Ahuja, S. S.; Bologna, R.; Sen, L.; Dolan, M.
J.; Ahuja, S. K. The influence of CCL3L1 gene-containing segmental
duplications on HIV-1/AIDS susceptibility. Science 2005, 307, 14334−
11440.
(16) LaPlante, S. R.; Edwards, P. J.; Fader, L. D.; Jakalian, A.; Hucke, O.
Revealing atropisomer axial chirality in drug discovery. ChemMedChem
2011, 6, 505−513.
(17) LaPlante, S. R.; Fader, L. D.; Fandrick, K. R.; Fandrick, D. R.;
Hucke, O.; Kemper, R.; Miller, S. P. F.; Edwards, P. J. Assessing
atropisomer axial chirality in drug discovery and development. J. Med.
Chem. 2011, 54, 7005−7022.
(18) Zhou, Y. S.; Tay, L. K.; Hughes, D.; Donahue, S. Simulation of the
impact of atropisomer interconversion on plasma exposure of
atropisomers of an endothelin receptor antagonist. J. Clin. Pharmacol.
2004, 44, 680−688.
(19) Parker, J. S.; Smith, N. A.; Welham, M. J.; Moss, W. O. New
approach to the rapid parallel development of four neurokinin
antagonists. Part 5. Preparation of ZM374979 cyanoacid and selective
crystallisation of ZM374979 atropisomers. Org. Process. Res. Dev. 2004,
8, 45−50.
D
dx.doi.org/10.1021/ml5004124 | ACS Med. Chem. Lett. XXXX, XXX, XXX−XXX